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Abstract
Human herpesvirus (HHV)-8 associated oncogenesis, a state of immune impairment, a local
inflammatory environment, angiogenesis and HIV infection occurring concurrently are important
factors for the development of HIV-associated Kaposi sarcoma (KS).
Activation of the interleukin (IL)-6 receptor signalling pathway and constitutive signalling of viral G
protein-coupled receptor (vGPCR) play an important role in the activation, proliferation and
transformation of HHV-8 infected endothelial cells thus contributing to the initiation and
progression of KS. HIV-tat protein, HIV-induced immune suppression and a hyperinflammatory
state facilitate the oncogenic activity of HHV-8.
In this article we reviewed some aspects of HIV-KS pathogenesis and tried to establish, according
to the available information in the literature, whether HIV-KS is a monoclonal neoplasm or a benign
angioproliferative disorder.
From the data of this review it is evident that most of the HIV-KS lesions are oligoclonal in origin.
It remains to be demonstrated whether these multiple monoclonal populations of cells are
neoplastic, harbouring specific cytogenetic alterations such as mutations, rearrangements and
amplifications, or are, as the current evidence shows, the result of HHV-8 induced intracellular
signalling pathways that modulate the expression of cellular genes associated with cell cycle
regulation, apoptosis, inflammatory response and angiogenesis, and represent a reactive
angioproliferative disorder.
Background
The clinical course of human immunodeficiency virus
(HIV)-associated Kaposi sarcoma (HIV-KS) ranges in
severity from a mild, slowly progressing to a rapidly pro-
gressing life threatening condition. Invariably, without
treatment, the overall prognosis of HIV-KS is poor [1].
The clonal nature of KS is controversial and the exact cell
of origin of KS is not clear. The cell of origin may arise
from lymphatic or blood endothelium, vascular smooth
muscle cells, mesenchymal cells or a combination of these
cells [2]. However, the current opinion is that KS probably
originates from lymphatic endothelium [3,4]. HHV-8
infection of blood vascular endothelial cells leads to lym-
phatic endothelial reprogramming of these cells [3,4], and
it is suggested that HHV-8 may preferentially infect
endothelial cell precursors and mediate their differentia-
tion towards a lymphatic endothelial cell genotype [4,5].
HHV-8 induced inflammation, angiogenesis and onco-
genesis are critical for the development of HIV-KS [6].
HHV-8 expresses several oncogenic proteins that are
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homologous to cellular proto-oncogenes. These include
vIL-6, vIL-8 receptor, chemokines of the macrophage
inflammatory protein (MIP) family, cell-cycle regulators
of the cyclin family and anti-apoptotic proteins of the bcl-
2 family. These biological mediators have the capacity to
activate several intracellular signaling pathways that may
bring about a hyperinflammatory state, angiogenesis and
transformation of endothelial cells. These events are cen-
tral to the initiation and promotion of HIV-KS [1].
It is unclear whether HIV-KS is a true neoplastic entity aris-
ing from a clonal expansion of a single HHV-8 infected
cell, or is a benign angioproliferative disorder. The dem-
onstration that HIV-KS lesions are monoclonal will pro-
vide further evidence on the probable malignant nature of
HIV-KS, since monoclonality is an important feature of
cancer.
In this article we reviewed the available data in the litera-
ture regarding the clonal nature of HIV-KS.
It is probable that HIV-KS starts as a polyclonal inflamma-
tory hyperplasia, and a subset of advanced HIV-KS
lesional cells undergo malignant transformation, which
may explain the aggressive clinical course of such cases
[7].
HHV-8
HHV-8 is aetiologically linked to KS, but is not sufficient
on its own to transform HHV-8 infected endothelial cells
and to initiate the development of KS. Other factors
including HIV-tat protein, a state of immune suppression
and dysregulation of cytokines, growth factors and adhe-
sion molecule functions cooperate with HHV-8 to drive
the initiation and promotion of HIV-KS [8].
HHV-8 gene expression is tightly controlled and occurs in
two phases: the latent phase that facilitates viral genome
persistence, and the lytic phase which consists of viral rep-
lication, host cell destruction and viral release [9]. During
the early stages of HHV-8 infection, cellular gene expres-
sion dominates, but as the viral infection progresses, and
viral DNA has entered the nucleus, latent and lytic viral
gene expression begins to overlap with that of the host,
resulting in a multifaceted intra- and intercellular signal-
ing cascade, which in turn is controlled by protein kinases
that phosphorylate serine, threonine and tyrosine resi-
dues of target cellular substrates, leading to the eventual
cellular transformation [9,10].
The early KS lesion is most probably initiated by HHV-8
induced production of pro-inflammatory cytokines IL-1,
IL-6, tumour necrosis factor (TNF)-α, interferon (IFN)-γ
and growth factors basic fibroblast growth factor (bFGF)
and vascular endothelial cell growth factor (VEGF) that
causes activation of endothelial cells followed by angio-
genesis (Diagram 1) [1,10-12].
In advanced KS lesions, HHV-8 oncogenes can alter the
regulation of intracellular signal transduction pathways,
cell cycle progression and apoptosis through the expres-
sion of several oncoproteins that are homologous to cel-
lular proto-oncogenes, including vIL-6, vIL-8 receptor,
MIP and anti-apoptotic proteins of the bcl-2 family. By
sabotaging the regulatory mechanisms of normal cellular
proliferation, differentiation and survival, the complex
combined expression of host and viral oncogenes contrib-
utes to tumour development (Diagram 1) [12].
Role of HHV-8 in the sarcomagenesis of KS
Latent and lytic HHV-8 gene products have the capacity to
target cellular apoptosis and host transcription pathways.
The inhibition of apoptosis leads to increased survival of
the infected cell, and the hijacking of the cellular tran-
scription machinery enables HHV-8 to overcome viral
gene transcription restriction. These events promote the
propagation of HHV-8 infection (Diagram 1) [9,10,13,
14].
Latent genes
HHV-8 latent proteins, including latency associated
nuclear antigen (LANA)-1, LANA-2, vCyclin, viral Fas-
associated death domain-like interleukin 1 gamma-con-
verting enzyme inhibitory protein (vFLIP) and kaposin
(Table 1), are expressed in all cells of advanced HIV-KS
lesions, and although their role in the sarcomagenesis of
KS has been confirmed, they are necessary but not suffi-
cient to cause the development of KS [15,16]. Tumour
hyperplasia and spindle cell proliferation are induced and
maintained by the action of these viral oncoproteins,
either acting alone, or in combination with each other
through paracrine mechanisms [15-17].
LANA-1 and LANA-2 may act as transcriptional regulators.
The expression of cellular and viral genes is modified by
the function of LANA [9,10]. By targeting the Rb-E2F
pathway and the p53 apoptosis control pathway, LANA is
able to inhibit cell death and promote cellular transfor-
mation [2,9,10]. In addition, LANA is critical for the per-
sistence of HHV-8 episomes. By anchoring the viral
episomes to the host DNA during interphase and mitosis,
Table 1: HHV-8 latent genes
Genes Products
ORF 73 LANA-1 and -2
ORF 72 vCyclin
ORF 71 vFlip
ORF K12 KaposinCancer Cell International 2008, 8:14 http://www.cancerci.com/content/8/1/14
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the efficient segregation of viral episomes to daughter cells
occurs in a synchronized and non-random fashion [9].
vFLIP is able to upregulate the expression and activation
of the transcription factors NF-κB and AP-1 (see lytic
genes below) that play a role in tumour cell survival dur-
ing the latent phase of HHV-8 infection [10,17].
Kaposin is another latent-phase gene product. This
unique HHV-8 oncoprotein, encoded by open reading
frame (ORF)-K12, is expressed in primary effusion lym-
phoma cell lines, can induce transformation in vitro, and
it has been suggested that it may play a role in the devel-
opment of KS [15,18,19].
Lytic genes
Some HHV-8 lytic genes (Table 1) play a major role in the
sarcomagenesis of KS [20]. vGPCR is an HHV-8 lytic gene
product that has been functionally linked to HHV-8-
mediated tumorigenesis [21]. vGPCR is a member of the
CXC-chemokine G protein-linked receptor family, shows
significant homology to the IL-8 receptors CXCR1 and
CXCR2, and exhibits ligand-independent activities. Con-
stitutive vGPCR signaling is augmented by chemokines
such as IL-8 and growth-related oncogene α that act as
vGPCR agonists [15,22]. Despite the fact that the expres-
sion of vGPCR is transient and is found only in 1–6% of
KS cells, vGPCR is able to initiate KS-like tumours in mice
[17,23].
Through constitutive activation of intracellular signaling
pathways, vGPCR has the capacity to transform endothe-
lial cells by promoting their uncontrolled proliferation
and by inhibition of apoptosis [6,11,12,15,21,22].
The increased secretion of angiogenic growth factors,
chemokines and cytokines induces either enhanced pro-
liferation of vGPCR-transformed endothelial cells in an
autocrine manner, or stimulates angioproliferation of
neighboring bystander cells by paracrine mechanisms
(Diagram 1) [12,14-17,21,22,24-27]. In addition, vGPCR
constitutive signaling may promote endothelial cell sur-
vival directly through the activation of Akt/protein kinase
B pathway (Akt/PKB) (Diagram 1) [7,15,16,22].
Stimulation of vGPCR leads to the activation of NF-κB,
activator protein (AP)-1 and nuclear factor of activated T
cells (NFAT), which induce the endogenous expression of
NF-κB and AP-1 dependant cytokines. These cytokines
include IL-1, TNF-α and IL-6 as well as growth factors
(Diagram 1) [17,27]. In addition, vGPCR signaling also
induces the upregulation of vascular endothelial cell
growth factor (VEGF) receptors. This facilitates the stimu-
lation of endothelial cells in an autocrine and paracrine
manner [20].
It is suggested that vGPCR in KS tumour cells activates
Akt/PKB in a paracrine and autocrine manner to promote
cell survival [16]. The autocrine pathway leads to the
induction of the angiogenic cell phenotype, whereas the
paracrine pathway maintains growth and proliferation
through the expression and secretion of various mediators
such as VEGF that promote angiogenesis (Diagram 1)
[21].
The activation of the serine-threonine kinase Akt by
vGPCR is critical for inhibition of apoptosis. Activated
Akt/PKB brings about inhibition of different pro-apop-
totic proteins, including the caspase family, and the con-
comitant activation of transcription factors that leads to
an increase in the expression of survival genes (Diagram 1,
blue arrows) [22,28].
It is suggested that through GTP binding molecules like
Rac, vGPCR can activate Akt/PKB, a critical molecule in
the control of cell survival and tumour development
[16,22]. Small GTP-binding proteins are the links
between the vGPCR and nuclear transcription factors. The
activation of Rac-GTPase by vGPCR expressed on HHV-8
infected endothelial cells in KS lesions stimulates the tran-
scription factors NF-κB and AP-1 (Diagram 1) [17]. By
preventing the vGPCR activation of Rac-1, the stimulation
of key transcription factors is blocked with the consequent
inhibition of cytokine secretion in vitro and sarcomagen-
esis in vivo [17].
In mice, constitutive activation of Rac-1 in endothelial
cells induces cell transformation and development of vas-
cular lesions that are very similar to experimental vascular
lesions initiated by constitutive activation of vGPCR.
However, these Rac-1 induced vascular lesions do not
develop into lesions that microscopically show sheets of
spindle cells and vascular slits with extravasated erythro-
cytes, features characteristic to human KS. This suggests
that in addition to constitutive activation of Rac-1, addi-
tional vGPCR-mediated signalling pathways are required
for the development of KS [17].
By activating the Ras, Raf and Rac intracellular signalling
pathways, vGPCR can induce the expression and secretion
of VEGF in an autocrine and paracrine manner. This proc-
ess involves the direct phosphorylation of hypoxia-induc-
ible factor (HIF)-1α, a transcription factor, by both the
p38 and MAPK signalling pathways. These pathways are
associated with VEGF production, and are present in
higher levels in HHV-8 transformed endothelial cells
(Diagram 1).
Cytokines and chemokines including IL-1, TNF-α and IL-
8 are also able to stimulate the p38 pathway leading to an
increased expression of VEGF and bFGF (Diagram 1, redCancer Cell International 2008, 8:14 http://www.cancerci.com/content/8/1/14
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arrows). The increased VEGF expression is sufficient for
cell transformation when ectopically expressed in murine
fibroblasts. Specific p38 and MAPK inhibitors have been
shown to diminish vGPCR-induced VEGF expression and
secretion. In addition VEGF is able to rescue cells from
apoptosis induced by serum starvation through the activa-
tion of the Akt/PKB pathway (Diagram 1, green arrow)
[12,15,21,22].
HHV-8 interferon regulatory factor (IRF) inhibits the
interferon signalling pathway and is able to induce
tumour formation. The expression of p21, a cyclin
dependant kinase (CDK) inhibitor, is downregulated by
vIRF, which enables the latent virus to evade the immune
mediated IFN cell-cycle shutdown, allowing HHV-8 to
establish persistence. However, vIRF is not expressed as
much in KS as in the cells of Castleman's disease and pri-
mary effusion lymphoma, and its role in the development
of KS is not clear [29].
It is probable that other viral lytic oncogenes, such as vIL-
6, also play a role in HHV-8 mediated cell cycle dysregu-
lation; however, its role in the sarcomagenesis of KS has
not yet been defined [29].
The clonal nature of HIV-KS lesions
Human x-linked androgen receptor (HUMARA) gene
Analysis of the inactivation pattern of HUMARA has been
used to determine the clonality of KS lesional cells in
females [30-33]. This method has three main drawbacks.
Firstly, it can only be performed on females, and since KS
affects males with a higher frequency than females, this
method cannot be used in all cases of KS. Secondly, at
times, there is contamination of KS biopsy specimens by
infiltration of normal tissue cells. Thirdly, the control
samples that the KS samples are compared to, may prove
to have unequal x-chromosome inactivation patterns that
lead to inaccurate results [31,34].
While some studies using the HUMARA technique
showed that the majority of KS cells were monoclonal
[32,33], others found that all KS lesions were polyclonal
[30] and still others found that KS lesions showed both
monoclonal and polyclonal characteristics [31] Therefore,
one needs to interpret studies of KS clonality using the
HUMARA technique with caution.
HHV-8 episomal studies
Judde and co-workers [34] studied the clonal nature of
HHV-8 terminal repeat sequences in advanced KS lesions
and found that such lesions display all patterns of clonal-
ity (Table 2). This finding supports the concept that KS
starts as a benign angioproliferative disorder comprising a
polyclonal cell population, and in later stages of HIV-KS
disease, some, if not all KS lesional cells will evolve to a
clonal cell population that will undergo expansion [34].
Duprez et al., [35] using the same HHV-8 episomal anal-
ysis like Judde et al., [34] demonstrated that most of the
advanced KS lesions were oligoclonal (82%), each indi-
vidual lesion having concurrently multiple HHV-8-
infected clones; and some of the advanced KS lesions were
monoclonal (18%), each lesion composed of a mono-
clonal expansion of a single HHV-8 infected cell (Table 3).
In addition, individual KS lesions that occur concurrently
at different anatomical sites in a subject with multicentric
KS, were either monoclonal or oligoclonal; and the size of
the HHV-8 episomes varied even between the multicentric
monoclonal KS lesions, clearly indicating that these
lesions arose from independent clones and were not met-
astatic lesions originating from the clonal expansion of
one HHV-8 infected cell.
Thus KS lesions may be regarded as a reactive proliferation
of oligoclonal or monoclonal endothelial cells and not as
a true malignancy. The fact that without treatment most
subjects with advanced HIV-KS and endemic KS die as a
consequence of their KS disease, may be explained by the
local aggressive nature of the multicentric lesions. KS
lesional cells show uncontrolled proliferation and
increased survival. When the lesions affect vital organs
such as the heart and the lungs, the disease is fatal [11].
However, one cannot exclude the possibility that in
advanced stages of HIV-KS disease, in the presence of
other as yet unidentified cofactors cooperating with HHV-
8 oncogenes, a subset of the benign monoclonal cells
evolve into a malignant clone that undergoes expansion
[7].
Conclusion
From the available data in the literature, one can conclude
that HIV-KS starts as a reactive polyclonal angioprolifera-
tive response towards HHV-8, and with time, some of the
polyclonal cells evolve to form oligoclonal cell popula-
tions that undergo expansion. This process is driven by
HHV-8 induced intracellular signalling pathways that
modulate the expression of cellular genes associated with
cell cycle regulation, apoptosis, inflammatory responses
Table 2: HHV-8 lytic genes
Genes Products
ORF 74 vGPCR
ORF K6 vMIP-II
ORF K1 vK1
ORF K9 vIRF-1
ORF K8.1 gBCancer Cell International 2008, 8:14 http://www.cancerci.com/content/8/1/14
Page 5 of 6
(page number not for citation purposes)
Table 3: Results for studies of KS clonality by TR analysis
Paper KS cases biopsies Result
monoclonal oligoclonal polyclonal excluded
1) Judde et al., 2000 26 n = 26 2 (7.6%) 4 (15.3%) 2 (7.6%) 18 (69.2%)
2) Duprez et al., 2007 98 n = 139 11 (7.9%) 48 (34.5%) 3 (2.1%) 77 (55.3%)
Total 124 n = 165 13 (7.8%) 52 (31.5%) 5 (3%) 95 (57.5%)
The signalling pathways mediated by vGPCR Figure 1
The signalling pathways mediated by vGPCR. Constitutive active vGPCR promotes the transcription of inflammatory 
cytokines and cell transformation. vGPCR through the Rac-NF-κB pathway promotes production of proinflammatory 
cytokines that in turn leads to recruitment and transformation of neighbouring cells by a paracrine mechanism. The pathway 
indicated by the red arrows show the activation of the P38 signalling pathway with the consequent increase in VEGF and bFGF 
production and secretion. The pathway indicated by the blue arrows shows the inactivation of pro-apoptotic genes (PAGI) and 
the activation of survival genes (SGEA). The green arrow shows activation of Akt/PKB by vGPCR-induced VEGF leading to cell 
survival.
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and angiogenesis. Whether these benign, reactive, multi-
ple monoclonal cell populations, under certain circum-
stances, undergo malignant transformation remains to be
elucidated.
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